- Home
- XFOR vs SVII Comparison
XFOR vs SVII Comparison
Compare XFOR & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- SVII
- Stock Information
- Founded
- XFOR 2014
- SVII 2021
- Country
- XFOR United States
- SVII United States
- Employees
- XFOR N/A
- SVII N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- SVII Blank Checks
- Sector
- XFOR Health Care
- SVII Finance
- Exchange
- XFOR Nasdaq
- SVII Nasdaq
- Market Cap
- XFOR 118.4M
- SVII 111.1M
- IPO Year
- XFOR N/A
- SVII 2022
- Fundamental
- Price
- XFOR $0.51
- SVII $11.27
- Analyst Decision
- XFOR Strong Buy
- SVII
- Analyst Count
- XFOR 3
- SVII 0
- Target Price
- XFOR $3.50
- SVII N/A
- AVG Volume (30 Days)
- XFOR 2.9M
- SVII 7.2K
- Earning Date
- XFOR 11-13-2024
- SVII 01-01-0001
- Dividend Yield
- XFOR N/A
- SVII N/A
- EPS Growth
- XFOR N/A
- SVII 13.16
- EPS
- XFOR N/A
- SVII 0.36
- Revenue
- XFOR $1,123,000.00
- SVII N/A
- Revenue This Year
- XFOR N/A
- SVII N/A
- Revenue Next Year
- XFOR $652.72
- SVII N/A
- P/E Ratio
- XFOR N/A
- SVII $31.25
- Revenue Growth
- XFOR N/A
- SVII N/A
- 52 Week Low
- XFOR $0.26
- SVII $10.86
- 52 Week High
- XFOR $1.60
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- XFOR 42.67
- SVII 58.63
- Support Level
- XFOR $0.43
- SVII $11.20
- Resistance Level
- XFOR $0.89
- SVII $11.24
- Average True Range (ATR)
- XFOR 0.09
- SVII 0.00
- MACD
- XFOR -0.04
- SVII 0.00
- Stochastic Oscillator
- XFOR 17.61
- SVII 100.00
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.